Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

ClinicalTrials.gov ID: NCT07010159

Public ClinicalTrials.gov record NCT07010159. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis

Study identification

NCT ID: NCT07010159
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Enrollment: 165 participants

Conditions and interventions

Conditions

Interventions

KPL-387 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 24, 2025
Primary completion: Dec 30, 2027
Completion: Dec 30, 2029
Last update posted: May 3, 2026

2025 – 2029

United States locations

U.S. sites: 23
U.S. states: 15
U.S. cities: 21

Facility	City	State	ZIP	Site status
Investigational Site 018	Gilbert	Arizona	85297	Recruiting
Investigational Site 030	Los Angeles	California	90048	Recruiting
Investigational Site 008	San Francisco	California	94158	Recruiting
Investigational Site 044	Santa Monica	California	90404	Recruiting
Investigational Site 016	Westminster	Colorado	80023	Recruiting
Investigational Site 001	Columbus	Georgia	31904	Withdrawn
Investigational Site 004	Chicago	Illinois	60611	Recruiting
Investigational Site 014	Indianapolis	Indiana	46184	Recruiting
Investigational Site 002	Overland Park	Kansas	66221	Withdrawn
Investigational Site 043	Baltimore	Maryland	21287	Recruiting
Investigational Site 012	Rochester	Minnesota	55905	Recruiting
Investigational Site 050	Kansas City	Missouri	64111	Recruiting
Investigational Site 046	Kansas City	Missouri	66160	Recruiting
Investigational Site 015	New York	New York	10016	Recruiting
Investigational Site 022	New York	New York	10032	Recruiting
Investigational Site 009	Cincinnati	Ohio	45219	Recruiting
Investigational Site 003	Cleveland	Ohio	44195	Recruiting
Investigational Site 005	Austin	Texas	78705	Recruiting
Investigational Site 013	Houston	Texas	77030	Recruiting
Investigational Site 042	Burlington	Vermont	05401	Recruiting
Investigational Site 006	Charlottesville	Virginia	22903	Recruiting
Investigational Site 023	Norfolk	Virginia	23507	Recruiting
Investigational Site 045	Richmond	Virginia	23284	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07010159, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 3, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07010159 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →